1/2
09:29 am
rxrx
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
Neutral
Report
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
1/1
08:00 am
rxrx
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
Low
Report
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
1/1
07:15 am
rxrx
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
Low
Report
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
12/29
12:11 pm
rxrx
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
Neutral
Report
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
12/28
12:57 pm
rxrx
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
12/24
12:08 pm
rxrx
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
Low
Report
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
12/22
10:34 am
rxrx
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
Low
Report
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
12/21
05:16 pm
rxrx
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
12/21
07:51 am
rxrx
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
Low
Report
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
12/18
11:39 am
rxrx
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
Medium
Report
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
12/17
08:45 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
12/17
05:10 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.
12/17
05:10 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at Morgan Stanley.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at Morgan Stanley.
12/10
02:58 pm
rxrx
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]
Low
Report
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]
12/8
07:30 am
rxrx
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Low
Report
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
12/5
07:03 pm
rxrx
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
12/4
07:55 pm
rxrx
Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]
Medium
Report
Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]
12/4
06:58 pm
rxrx
Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]
Medium
Report
Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]
12/1
08:30 am
rxrx
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
Medium
Report
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
11/19
07:04 pm
rxrx
Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]
Medium
Report
Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]
11/18
10:17 am
rxrx
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? [Seeking Alpha]
Medium
Report
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? [Seeking Alpha]
11/18
08:45 am
rxrx
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Low
Report
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
11/13
09:42 am
rxrx
Tempus: Diagnostics Substance, AI Flash [Seeking Alpha]
Medium
Report
Tempus: Diagnostics Substance, AI Flash [Seeking Alpha]
11/12
10:51 am
rxrx
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock [Yahoo! Finance]
Low
Report
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock [Yahoo! Finance]
11/5
06:30 am
rxrx
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update